Roche announced promising late-breaking data from its obesity portfolio, set to be presented at the ADA 2026 Scientific Sessions. The data highlights the efficacy and safety of enicepatide (CT-388) and petrelintide. Enicepatide, a dual GLP-1/GIP receptor agonist, showed significant weight loss in a Phase II study. Petrelintide, an investigational amylin analog, demonstrated positive results in the ZUPREME-1 Phase II trial. Roche plans to initiate a Phase II multi-arm combination trial of enicepatide and petrelintide in mid-2026. These developments aim to offer tailored treatment options for people with overweight or obesity. The company emphasizes the potential of these drugs to improve long-term treatment adherence. Both compounds are advancing into Phase III development. More detailed findings will also be presented during a virtual event on June 8, 2026. The company is committed to addressing the global obesity crisis. Roche is also evaluating enicepatide in a study for patients with type 2 diabetes.